CJC-1295 (with DAC)

Growth Hormone Secretagogue (GHRH Analog)research

Also known as: CJC-1295 DAC, Drug Affinity Complex CJC-1295, DAC:GRF

A long-acting growth hormone-releasing hormone (GHRH) analog with a Drug Affinity Complex that extends its half-life to 6-8 days, producing sustained elevated growth hormone and IGF-1 levels.

Overview

CJC-1295 with DAC is a synthetic analog of growth hormone-releasing hormone (GHRH) consisting of 30 amino acids with a Drug Affinity Complex (DAC) covalently attached. The DAC binds to albumin in the bloodstream, dramatically extending the peptide's half-life from minutes to 6-8 days. This allows for once or twice weekly dosing while maintaining persistently elevated growth hormone (GH) and insulin-like growth factor 1 (IGF-1) levels. Unlike GHRH analogs without DAC, this version creates a sustained GH elevation rather than mimicking natural pulsatile release, which has both advantages (convenience, consistent levels) and disadvantages (potential blunting of natural GH pulsatility, more side effects). It was originally developed by ConjuChem Biotechnologies and studied in clinical trials before the company ceased operations.

Mechanism of Action

CJC-1295 with DAC works by: (1) Binding to GHRH receptors on the anterior pituitary gland to stimulate growth hormone synthesis and secretion; (2) The DAC moiety binds to serum albumin via reactive chemistry, creating a long-circulating depot that continuously stimulates GH release; (3) Elevates IGF-1 levels through sustained GH stimulation of hepatic IGF-1 production; (4) Unlike natural GHRH, maintains a persistently elevated baseline GH level rather than pulsatile release; (5) Does not significantly affect other pituitary hormones (ACTH, LH, FSH, TSH, prolactin).

Molecular Weight

~3647.28 g/mol (peptide) + DAC

Sequence

Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-Lys(DAC)-NH2

Dosage Protocols

Dose Range

1mg2mg

Frequency

Once or twice per week

Route

subcutaneous

Cycle Length

8-12 weeks on, 4 weeks off

Due to the long half-life, once or twice weekly dosing is sufficient. Inject in the evening to complement natural GH release during sleep.

Source: Clinical trial protocols and community guidelines

Side Effects

EffectSeverity
Water retentionmild
Injection site reactionsmild
Numbness/tingling in extremitiesmild
Headachemild
Fatiguemild
Elevated fasting glucosemoderate
Joint painmild

Pros & Cons

Convenient dosing — only 1-2 injections per week due to extended half-life

Sustained, consistent elevation of GH and IGF-1 levels

Clinical trial data showing dose-dependent IGF-1 increases

Stimulates endogenous GH production rather than replacing it

Sustained GH elevation is non-physiological — natural GH is pulsatile, not continuous

More side effects (water retention, numbness) compared to non-DAC version due to constant GH elevation

Potential for receptor desensitization with prolonged use, requiring cycling

Development discontinued by original manufacturer; limited clinical data

Cannot fine-tune timing of GH pulses (e.g., pre-sleep) as with non-DAC version

Research Studies

Legal Status

Not FDA-approved. Available as a research chemical. Banned by WADA. Was in clinical trials (Phase 2) before development was discontinued.

Related Peptides